John Valliant
Founder at FUSN PHAR
Net worth: 7 M $ as of 2024-04-29
John Valliant active positions
| Companies | Position | Start | End |
|---|---|---|---|
| FUSN PHAR | Director/Board Member | 2014-11-30 | - |
| Chief Executive Officer | 2014-11-30 | - | |
| Founder | 2014-11-30 | - | |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Director/Board Member | 2008-02-29 | - |
| Founder | 2008-02-29 | - | |
| Independent Dir/Board Member | 2008-02-29 | - | |
| McMaster University | Corporate Officer/Principal | 1998-12-31 | - |
Career history of John Valliant
Training of John Valliant
| McMaster University | Doctorate Degree |
Statistics
International
| Canada | 4 |
Operational
| Director/Board Member | 2 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| FUSN PHAR | Health Technology |
| Private companies | 1 |
|---|---|
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Health Technology |
- Stock Market
- Insiders
- John Valliant
- Experience
